- Conditions
- Overweight or Obesity
- Interventions
- TERN-601, Matching Placebo
- Drug · Other
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 431
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Smoking Cessation
- Interventions
- Exenatide, NRT, Counseling, Placebo
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes Mellitus, Healthy
- Interventions
- GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Overweight, Obesity
- Interventions
- Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Fullerton, California • Huntington Beach, California + 15 more
- Conditions
- Obesity, Overweight
- Interventions
- Tirzepatide, LY3841136, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
- Conditions
- Bariatric Surgery
- Interventions
- GLP-1
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes
- Interventions
- glucagon like peptide-1, glucose control
- Drug · Dietary Supplement
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Type 1 Diabetes
- Interventions
- Liraglutide, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 15 Years to 30 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Obesity
- Interventions
- Cagrilintide, Semaglutide, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 809 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Costa Mesa, California + 39 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- Tirzepatide, Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 142
- States / cities
- Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 123 more
- Conditions
- Obesity, Methamphetamine Use Disorder
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Obesity
- Interventions
- Liraglutide, Oral Semaglutide, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Obesity, Breast Cancer Risk
- Interventions
- tirzepatide
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 40 Years to 64 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Westwood, Kansas
- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
- Interventions
- Dulaglutide 0.75Mg/0.5Ml Inj Pen
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania
- Conditions
- Overweight and Obesity
- Interventions
- Apitegromab, Placebo, Tirzepatide
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1, Glucagon
- Interventions
- GB, Placebo
- Dietary Supplement
- Lead sponsor
- Lawry Han
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Cancers
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 1 Diabetes
- Interventions
- CT-868, Placebo, Victoza
- Drug
- Lead sponsor
- Carmot Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Prostate Carcinoma, Recurrent Prostate Carcinoma
- Interventions
- Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection, Cardiac Computerized Tomographic Angiography, Computed Tomography, Electronic Health Record Review, Internet-Based Intervention, Lifestyle Counseling, Medical Device Usage and Evaluation, Nutritional Intervention, Questionnaire Administration, Radiation Therapy, Referral, Semaglutide, Short-Term Fasting, Tirzepatide
- Drug · Behavioral · Procedure + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 30 Years to 79 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Diabetes
- Interventions
- GLP-1
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
- Interventions
- Discontinuation and Reinitiation of Tirzepatide
- Other
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Glucagon-Like Peptide- 1 (GLP-1) infusion, Placebo Comparator: Saline Infusion
- Drug · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes, Hypertriglyceridemia
- Interventions
- Saxagliptin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Severe Obesity, Obesity, BMI Greater Than 30
- Interventions
- Tirzepatide, Standard of Care post-gastric bypass
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee